Overview

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center